Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic BCG for the Prevention of Postoperative Recurrence of Non-muscle-invasive Bladder Cancer
NCT06747455Phase 3Active, not recruiting
- Sponsor
- Zhifei Biological
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Zhifei Biological. Started Apr 2025; status: active, not recruiting.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06747455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06747455.